Target- |
MechanismDystrophin expression stimulants [+1] |
|
|
|
Inactive Indication- |
Drug Highest PhasePhase 1/2 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Phase 1/2a, Monocentric, Open Label Study to Evaluate the Safety, PK and PD of SQY51 in Paediatric and Adult Patients With a Genetically Confirmed Diagnosis of Duchenne Muscular Dystrophy
This is a Phase 1/2a, monocentric, open label study to evaluate the safety, pharmacokinetics, and pharmacodynamics of SQY51 in patients with Duchenne muscular dystrophy
100 Clinical Results associated with SQY Therapeutics
0 Patents (Medical) associated with SQY Therapeutics
100 Deals associated with SQY Therapeutics
100 Translational Medicine associated with SQY Therapeutics